3901 Greenspring Ave.
Baltimore, MD 21211
Dr. Stephanie Morris is the medical director for the Center for Autism Services, Science and Innovation (CASSI™, formerly known as the Center for Autism and Related Disorders, or CARD) Kennedy Krieger Institute. A neurologist with special qualifications in child neurology, Dr. Morris is also an assistant professor in the Department of Neurology at the Johns Hopkins University School of Medicine. Dr. Morris’s primary clinical interest is on the diagnosis and medical management of children with intellectual and developmental disabilities, especially as they occur in the context of genetic conditions such as Fragile X syndrome and Neurofibromatosis Type 1 (NF1).
Dr. Morris completed her Bachelors of Science degree in Molecular and Cellular Biology from the University of Arizona, and obtained her MD in 2011 from the University of Arizona College of Medicine – Phoenix. She completed her Pediatric Neurology training at Washington University in 2016, serving as administrative chief resident during her last year of residency, and subsequently joined the faculty at Washington University.
While on faculty at Washington University, Dr. Morris served as director of the Neurofibromatosis (NF) and Fragile X Clinical Programs, section head for the general pediatric neurology in the Division of Child Neurology and assistant director of the Clinical Trials Unit for the Washington University Intellectual and Developmental Disabilities Research Center (IDDRC). Additionally, Dr. Morris served as a member of the Clinical Competency Committee for both the Pediatrics and Pediatric Neurology Residency Programs, the Pediatric Clinical Research Unit Oversight Committee and the Program Evaluation Committee for the Pediatric Neurology Residency at Washington University.
In June 2022, Dr. Morris joined the faculty at Kennedy Krieger and the Johns Hopkins University School of Medicine and currently serves at the medical director for CASSI.
Dr. Morris was awarded the Neurological Sciences Academic Development Award from the National Institute of Neurological Disorders and Stroke (NINDS) in 2015, and subsequently led the largest international collaborative study on quantitative autistic trait burden in Neurofibromatosis Type 1 (NF1) under the co-mentorship of Dr. David H. Gutmann and Dr. John N. Constantino at Washington University in St. Louis. Additionally, Dr. Morris served as the site P.I. at Washington University for a double-blind placebo-controlled clinical trial through NeuroNEXT investigating the effects of an investigational medication on language learning in children with Fragile X Syndrome (FX Learn) and was awarded the NeuroNEXT Fellowship Award in 2018. She has led several observational studies investigating genotype-phenotype correlations for quantitative autistic trait burden in NF1, examining the neuropsychological profile of children with NF1, evaluating the radiographic features that differentiate neoplastic from non-neoplastic brain lesions in children with NF1 and using predictive modeling to predict clinical features in NF1. Dr. Morris has co-authored many other peer-reviewed articles.